1. Home
  2. MIRM vs HLN Comparison

MIRM vs HLN Comparison

Compare MIRM & HLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIRM
  • HLN
  • Stock Information
  • Founded
  • MIRM 2018
  • HLN 2022
  • Country
  • MIRM United States
  • HLN United Kingdom
  • Employees
  • MIRM N/A
  • HLN N/A
  • Industry
  • MIRM Biotechnology: Pharmaceutical Preparations
  • HLN Package Goods/Cosmetics
  • Sector
  • MIRM Health Care
  • HLN Consumer Discretionary
  • Exchange
  • MIRM Nasdaq
  • HLN Nasdaq
  • Market Cap
  • MIRM 1.9B
  • HLN 45.6B
  • IPO Year
  • MIRM 2019
  • HLN N/A
  • Fundamental
  • Price
  • MIRM $39.10
  • HLN $10.22
  • Analyst Decision
  • MIRM Strong Buy
  • HLN Buy
  • Analyst Count
  • MIRM 11
  • HLN 1
  • Target Price
  • MIRM $58.55
  • HLN $10.95
  • AVG Volume (30 Days)
  • MIRM 476.2K
  • HLN 13.6M
  • Earning Date
  • MIRM 05-07-2025
  • HLN 02-27-2025
  • Dividend Yield
  • MIRM N/A
  • HLN 1.65%
  • EPS Growth
  • MIRM N/A
  • HLN 38.94
  • EPS
  • MIRM N/A
  • HLN 0.20
  • Revenue
  • MIRM $336,888,000.00
  • HLN $14,062,871,660.00
  • Revenue This Year
  • MIRM $29.51
  • HLN $5.66
  • Revenue Next Year
  • MIRM $20.27
  • HLN $4.86
  • P/E Ratio
  • MIRM N/A
  • HLN $25.21
  • Revenue Growth
  • MIRM 80.76
  • HLN N/A
  • 52 Week Low
  • MIRM $23.14
  • HLN $8.06
  • 52 Week High
  • MIRM $54.23
  • HLN $10.80
  • Technical
  • Relative Strength Index (RSI)
  • MIRM 34.64
  • HLN 54.81
  • Support Level
  • MIRM $37.83
  • HLN $9.18
  • Resistance Level
  • MIRM $40.32
  • HLN $9.74
  • Average True Range (ATR)
  • MIRM 2.47
  • HLN 0.25
  • MACD
  • MIRM -0.33
  • HLN 0.03
  • Stochastic Oscillator
  • MIRM 25.14
  • HLN 74.55

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About HLN Haleon plc (Each representing two)

Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.

Share on Social Networks: